Meridian Bioscience Aktie

Meridian Bioscience EBIT-margin

EBIT-margin (driftsmargin) for Meridian Bioscience (VIVO) pr. 20. aug. 2026 er 22,70 %. I foregående år var EBIT-margin (driftsmargin) 32,03 % — en ændring på -29,13 % (lavere).

EBIT-margin

22,70 %

YoY

-29,13%

Senest opdateret:

EBIT-margin (driftsmargin) for Meridian Bioscience er 2026 22,70 % . EBIT-margin (driftsmargin) for Meridian Bioscience var 2025 32,03 % . Det falder dermed med -29,13% lavere sammenlignet med året før.

For Meridian Bioscience, the operating (EBIT) margin of 22,7% is up versus 20,9% a few years ago.

Access this data via the Eulerpool API

Meridian Bioscience Aktieanalyse

Hvad laver Meridian Bioscience? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Meridian Bioscience aktie

EBIT-margin (driftsmargin) for Meridian Bioscience er 22,70 % i 2026.

EBIT-margin (driftsmargin) for Meridian Bioscience ændrede sig fra 32,03 % til 22,70 %, hvilket repræsenterer en ændring på -29,13 %. Værdien er lavere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EBIT-margin (driftsmargin) Meridian Bioscience siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EBIT-marginen måler driftsrentabilitet som en procentdel af omsætningen. Den viser, hvor meget overskud en virksomhed genererer fra driften før renter og skatter.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne EBIT-margin (driftsmargin)s Meridian Bioscience med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

For at evaluere EBIT-margin (driftsmargin)s er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for EBIT-margin (driftsmargin).

Access this data via the Eulerpool API

Marginer — Meridian Bioscience

Alle nøgletal — Meridian Bioscience